MASAMI YAMAUCHI

Last Updated :2023/11/02

Affiliations, Positions
Hiroshima University Hospital(Medical), Associate Professor or Lecturer
E-mail
myamauchihiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2019/05/01, Hiroshima University, Hospital, Lecturer

Academic Degrees

  • Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Gastroenterology

Research Keywords

  • Cancer Education
  • Cancer Treatment

Educational Activity

Course in Charge

  1. 2023, Undergraduate Education, Intensive, Practice of Medicine I
  2. 2023, Undergraduate Education, Intensive, Practice of Medicine II

Research Activities

Academic Papers

  1. ★, Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients, Int J Cancer, 142(7), 1418-1426, 20180401
    Link to Paper Search Results by DOI
  2. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3(3), 348-355, 201903
    Link to Paper Search Results by DOI
  3. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54(7), 650-659, 201907
    Link to Paper Search Results by DOI
  4. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12(4), 341-346, 20190801
    Link to Paper Search Results by DOI
  5. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 97(2), 75-81, 2019
    Link to Paper Search Results by DOI
  6. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy, SCIENTIFIC REPORTS, 9, 20190820
    Link to Paper Search Results by DOI
  7. Long-term survival of a patient with stage IV basaloid squamous carcinoma of the esophagus with lung metastases following combined modality therapy, Nihon Shokakibyo Gakkai Zasshi, 112(8), 1503-1509, 201508
    Link to Paper Search Results by DOI
  8. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study), Int J Clin Oncol, 24(10), 1223-1230, 20190529
    Link to Paper Search Results by DOI
  9. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, J Gastroenterol, 20, 20190904
    Link to Paper Search Results by DOI
  10. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, Clin J Gastroenterol, 20190828
    Link to Paper Search Results by DOI
  11. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124, 202003
    Link to Paper Search Results by DOI
  12. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection, INTERNAL MEDICINE, 59(7), 941-944, 2020
    Link to Paper Search Results by DOI
  13. Isolated cardiac metastases of hepatocellular carcinoma after resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(3), 421-427, 202006
    Link to Paper Search Results by DOI
  14. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12, 202005
    Link to Paper Search Results by DOI
  15. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50(7), 885-888, 202007
    Link to Paper Search Results by DOI
  16. ★, Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11, 202005
  17. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35(8), 1412-1419, 202008
    Link to Paper Search Results by DOI
  18. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(5), 867-872, 202010
    Link to Paper Search Results by DOI
  19. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(5), 839-843, 202010
    Link to Paper Search Results by DOI
  20. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50(11), 1222-1233, 202011
    Link to Paper Search Results by DOI
  21. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 98(11), 787-797, 202011
    Link to Paper Search Results by DOI
  22. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28(2), 400-409, 202102
    Link to Paper Search Results by DOI
  23. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222(12), 2061-2070, 20201215
    Link to Paper Search Results by DOI
  24. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(1), 283-287, 202102
    Link to Paper Search Results by DOI
  25. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures, INTERNAL MEDICINE, 60(6), 829-837, 2021
    Link to Paper Search Results by DOI
  26. A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system, IDCASES, 23, 2021
    Link to Paper Search Results by DOI
  27. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy, ONCOLOGY, 99(5), 327-335, 202104
    Link to Paper Search Results by DOI
  28. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559, 78-83, 20210625
    Link to Paper Search Results by DOI
  29. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism, MOLECULAR MEDICINE REPORTS, 23(1), 202101
    Link to Paper Search Results by DOI
  30. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 36(6), 1685-1693, 202106
    Link to Paper Search Results by DOI
  31. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40(1), 20210626
    Link to Paper Search Results by DOI
  32. Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients, MEDICINE, 100(26), 20210702
    Link to Paper Search Results by DOI
  33. Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib, INTERNAL MEDICINE, 60(13), 2047-2053, 2021
    Link to Paper Search Results by DOI
  34. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma, ONCOLOGY, 99(8), 507-517, 202107
    Link to Paper Search Results by DOI
  35. Clinical Outcomes of 2nd-and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma, ONCOLOGY, 99(8), 491-498, 202107
    Link to Paper Search Results by DOI
  36. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21(1), 20210731
    Link to Paper Search Results by DOI
  37. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28(9), 1304-1311, 202109
    Link to Paper Search Results by DOI

Invited Lecture, Oral Presentation, Poster Presentation

  1. TUMOR AND BLOOD FGFR4 LEVELS PREDICT THE EFFICACY OF LENVATINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA, Masami Yamauchi, Atsushi Ono, Haruna Hatooka, Kenichiro Kodama, Peiyi Zhang, Yuji Teraoka, Kei Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Clair Nelson Hayes, Hiroshi Aikata, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019/11/09, Without Invitation, Japanese
  2. REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab vs. Reverse Sequence for Colorectal Cancer, Masami Yamauchi, Kohei Shitara, Takeharu Yamanaka, Tadamichi Denda, Yasushi Tsuji, Yoshito Komatsu, Yoshimitsu Kobayashi, Junji Furuse, Takeshi Kato, Eiji Oki, Takashi Ando, Yasuhiro Hagiwara, Yasuo Ohashi, Takayuki Yoshino, 2018 the Japanese Society of Medical Oncology Annual Meeting, 2018/07/19, Without Invitation, Japanese
  3. Serial profiling of circulating tumor DNA identifies biomarkers for anti-VEGF chemotherapy in mCRC patients, Yamauchi, Masami; Chayama, Kazuaki; Urabe, Yuji; Ono, Atsushi; Ochi, Hidenori; Miki, Daiki, 第15回日本臨床腫瘍学会学術集会, 2017/07, Without Invitation, Japanese
  4. A COMPREHENSIVE ANALYSIS OF A WIDE RANGE OF LIVER DISEASES BY 16S rRNA SEQUENCING REVEALS CHARACTERISTIC PATTERNS OF GUT MICROBIOTA IN EACH ETIOLOGY, Daiki Miki, Yumi Shimomura, Nelson Hayes, Hiromi Abe-Chayama, Hatsue Fujino, Maiko Numba, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Grace Naswa Makokha, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019/11/11, Without Invitation, English
  5. INDEPENDENT IMPACT OF POLYMORPHISM IN IRF5 AS WELL AS STAT4 ON HBV-RELATED HEPATOCARCINOGENESIS, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Nelson Hayes, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019/11/11, Without Invitation, English
  6. ASSOCIATION OF FNDC5, PNPLA3 AND TM6SF2 POLYMORPHISMS WITH HEPATIC STEATOSIS IN NAFLD PATIENTS, Daiki Miki, Takashi Nakahara, Eisuke Murakami, Hiromi Abe-Chayama, Hatsue Fujino, Atsushi Ono, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Nelson Hayes, Grace Naswa Makokha, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019/11/10, Without Invitation, English
  7. DIFFERENTIAL EFFECTS OF HOST GENETIC FACTORS ON HCV PERSISTENCE ACCORDING TO HCV GENOTYPES, Daiki Miki, Tomokazu Kawaoka, Nelson Hayes, Hiromi Abe-Chayama, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019/11/10, Without Invitation, English
  8. PERMISSION OF HEPATITIS B VIRUS INFECTION IN Jak3KORag2KO MOUSE, Yuji Teraoka, Michio Imamura, Takuro Uchida, Kazuki Ohya, Mitsutaka Osawa, Kei Morio, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Daiki Miki, Akira Hiramatsu, Hiromi Abe-Chayama, Nelson Hayes, Yuji Ishida, Chise Tateno, Hiroshi Aikata, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019/11/09, Without Invitation, English
  9. GENETIC POLYMORPHISM OF IP-10, NOT IFNL4 OR HLA-DPS, AFFECTS LIVER INFLAMMATION IN CHRONIC HEPATITIS B PATIENTS, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Nelson Hayes, Hatsue Fujino, Grace Naswa Makokha, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019/11/08, Without Invitation, English
  10. EXPLORATORY ANALYSIS OF BIOMARKERS ASSOCIATED WITH CLINICAL OUTCOMES OF LENVATINIB IN HEPATOCELLULAR CARCINOMA, Atsushi Ono, Hiroshi Aikata, Masami Yamauchi, Kenichiro Kodama, Daiki Miki, Waka Ohishi, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Hiromi Abe-Chayama, Masataka Tsuge, Michio Imamura, Clair Nelson Hayes, Kazuaki Chayama, The Liver Meeting 2019, American Association for the Study of Liver Diseases, 2019/11/08, Without Invitation, English
  11. IRF5高発現に関連するSNPアレルはHBV関連肝癌の発症リスクを低下させる, 三木大樹、柘植雅貴、山内理海、大野敦司、相方浩、角田達彦、茶山一彰, 2019/09/26, Without Invitation, Japanese
  12. 膵癌患者の血中exosome のテトラスパニン発現プロファイル, 辰川裕美子、三木大樹、芹川正浩、池本珠莉、平野哲朗、吹上綾美、森豪、中村真也、斎藤裕平、河村良太、津島健、栗原啓介、壷井智史、石井康隆、山内理海、茶山一彰, 第105回日本消化器病学会総会, 日本消化器病学会, 2019/05/10, Without Invitation, Japanese
  13. Multiple genetic factors affecting nonalcoholic fatty liver disease and nonalcoholic steatohepatitis-related hepatocellular carcinoma in the Japanese population, Daiki Miki, Yuichi Hiyama, Atsushi Ono, Masami Yamauchi, Masataka Tsuge, Hiroshi Aikata, Tatsuhiko Tsunoda, Kazuaki Chayama, 11th AACR-JCA Joint Conference, 2019/02/10, Without Invitation, English
  14. Association of TLL1 Polymorphism with Development of Hepatocellular Carcinoma after Hepatitis C Virus Eradication and Fibrosis Severity, Daiki Miki, Tomokazu Kawaoka, Yuko Nagaoki, Nelson Hayes, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hiroshi Aikata, Hiromi Abe-Chayama, Hidenori Ochi, Tatsuhiko Tsunoda, Kazuaki Chayama, The Liver Meeting 2018, American Association for the Study of Liver Diseases, 2018/11/10, Without Invitation, English

Awards

  1. 2019, Poster of Distinction, AASLD, TUMOR AND BLOOD FGFR4 LEVELS PREDICT THE EFFICACY OF LENVATINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA